The Cooper Companies, Inc. $COO Holdings Lifted by Boston Trust Walden Corp

Boston Trust Walden Corp raised its position in The Cooper Companies, Inc. (NASDAQ:COO) by 2.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,494,960 shares of the medical device company’s stock after purchasing an additional 29,339 shares during the quarter. Cooper Companies comprises approximately 0.8% of Boston Trust Walden Corp’s investment portfolio, making the stock its 29th biggest holding. Boston Trust Walden Corp’s holdings in Cooper Companies were worth $102,494,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Buckhead Capital Management LLC grew its stake in shares of Cooper Companies by 14.3% in the third quarter. Buckhead Capital Management LLC now owns 58,930 shares of the medical device company’s stock worth $4,040,000 after purchasing an additional 7,368 shares in the last quarter. Amundi raised its stake in shares of Cooper Companies by 35.5% during the second quarter. Amundi now owns 1,331,480 shares of the medical device company’s stock valued at $97,225,000 after purchasing an additional 348,652 shares in the last quarter. Westwood Holdings Group Inc. lifted its holdings in Cooper Companies by 23.4% in the second quarter. Westwood Holdings Group Inc. now owns 311,745 shares of the medical device company’s stock worth $22,184,000 after purchasing an additional 59,190 shares during the period. Janney Montgomery Scott LLC lifted its holdings in Cooper Companies by 5.1% in the second quarter. Janney Montgomery Scott LLC now owns 97,394 shares of the medical device company’s stock worth $6,931,000 after purchasing an additional 4,761 shares during the period. Finally, United Services Automobile Association bought a new position in Cooper Companies in the 1st quarter valued at about $414,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Lawrence Erik Kurzius acquired 2,000 shares of Cooper Companies stock in a transaction on Wednesday, December 17th. The stock was bought at an average cost of $82.50 per share, with a total value of $165,000.00. Following the completion of the purchase, the director owned 7,777 shares of the company’s stock, valued at $641,602.50. This represents a 34.62% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Holly R. Sheffield bought 1,230 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was purchased at an average price of $80.75 per share, with a total value of $99,322.50. Following the completion of the acquisition, the insider owned 39,052 shares of the company’s stock, valued at approximately $3,153,449. This trade represents a 3.25% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 16,014 shares of company stock worth $1,304,416 over the last three months. Company insiders own 1.98% of the company’s stock.

Cooper Companies Trading Up 0.1%

Shares of NASDAQ:COO opened at $82.62 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. The stock has a market capitalization of $16.19 billion, a price-to-earnings ratio of 43.95, a PEG ratio of 2.36 and a beta of 1.05. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $100.24. The company has a 50 day moving average price of $75.92 and a 200 day moving average price of $72.45.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its board has approved a share repurchase program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research firms have commented on COO. Citigroup restated a “neutral” rating and set a $88.00 price target (up from $72.00) on shares of Cooper Companies in a research report on Monday, December 8th. Wells Fargo & Company boosted their target price on Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, December 5th. Mizuho set a $100.00 target price on Cooper Companies and gave the stock an “outperform” rating in a research report on Friday, December 5th. JPMorgan Chase & Co. lifted their price target on Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, December 5th. Finally, Robert W. Baird boosted their price objective on Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $90.15.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Zacks Research raised multiple near‑ and medium‑term EPS forecasts (including FY2026 to $4.45, FY2027 to $4.84 and FY2028 to $5.33) and lifted several quarterly estimates — this improves the earnings trajectory and supports valuation multiple expansion.
• Positive Sentiment: Zacks specifically increased Q1 2026 to $1.02, Q2 2026 to $1.07, Q3 2026 to $1.16 and Q4 2026 to $1.20 (and raised several 2027 quarter estimates), signaling confidence in near‑term revenue/margin trends.
• Positive Sentiment: Brokerage consensus flagged a “Moderate Buy” for COO, which can attract incremental demand from models and investors that follow analyst ratings. Article Title
• Neutral Sentiment: A Zacks comparison piece examines COO vs. Merit Medical (MMSI) for value investors — useful for relative‑value decisions but not a direct catalyst. Article Title
• Neutral Sentiment: December short‑interest data in the report is effectively zero/NaN and appears unreliable; it provides no actionable signal on short pressure or squeeze risk at present.
• Negative Sentiment: One small downward tweak: Zacks trimmed Q3 2027 EPS from $1.25 to $1.24 — a minor cut that slightly offsets some upgrades but is not material to the overall upward revisions.

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.